-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
Author: Shi Bei
On September 16, OSE and Boehringer Ingelheim (BI) jointly announced the first-in-class selective SIRPα inhibitor BI 765063 combined with PD-1 monoclonal antibody BI 754091 (ezabenlimab) to treat patients with advanced solid tumors in phase I dose escalation positive data
.
The CD47-SIRPa interaction blocks immune cell activation, leading to tumor cell growth
.
At present, a number of monoclonal antibodies targeting CD47 have entered phase III clinical trials around the world
The data of phase I dose escalation shows that BI 765063 as a single agent or combined with PD-1 monoclonal antibody BI 754091 (ezabenlimab) for the treatment of a large number of pretreated patients with advanced solid tumors has good tolerability and activity
.
As of June 2021, a total of 18 patients have received treatment (16 of which can be evaluated for efficacy)
The following are the key findings of this research:
The combination of BI 765063 and BI 745091 was well tolerated, without dose-limiting toxicity (DLTs), and did not reach the maximum tolerated dose (MTD)
.
Among patients with microsatellite stable (MSS) advanced endometrial or colorectal cancer, 3 patients achieved partial remission (PR)
The two companies are currently recruiting patients with MSS advanced colorectal cancer and advanced endometrial cancer in a phase I expansion study (Part 2)
